Transglutaminase in epidermis and neurological disease or what makes a good cross-linking substrate

Advances in Enzymology and Related Areas of Molecular Biology

Volumn 78 1, Issue , 2011, Pages 97-160

  Hoffner, Guylaine ^a   Vanhoutteghem, Amandine ^a   André, William ^a   Djian, Philippe ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CROSS LINKING REAGENT; PEPTIDE; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ALZHEIMER DISEASE; ANIMAL; CYTOLOGY; ENZYME SPECIFICITY; EPIDERMIS; GENETICS; HUMAN; KERATINOCYTE; METABOLISM; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CROSS-LINKING REAGENTS; EPIDERMIS; HUMANS; KERATINOCYTES; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; PEPTIDES; SUBSTRATE SPECIFICITY; TRANSGLUTAMINASES;

EID: 84856616697     PISSN: 0065258X     EISSN: None     Source Type: Book Series    
DOI: 10.1002/9781118105771.ch3     Document Type: Article

References (354)

1. Mycek, M., Clatke, D., Neidle, A., and Waelsch, H. (1959) Amine incorporation into insulin as catalyzed by transglutaminase, Arch. Biochem. Biophys. 84, 528-540.
2. Pisano, J., Finlayson, J., and Peyton, M. (1968) Cross-link in fibrin polymerized by factor 13: ε-(γ-glutamyl)lysine, Science 160, 892-893.
3. Green, H. (1979) The keratinocyte as differentiated cell type, Harvey Lect. 74, 101-139.
4. Zatloukal, K., Fesus, L., Denk, H., Tarcsa, E., Spurej, G., and B̈ock, G. (1992) High amount of ε-(γ-glutamyl)lysine cross-links in Mallory bodies, Lab. Invest. 66, 774-777.
5. Strnad, P., Harada, M., Siegel, M., Terkeltaub, R., Graham, R., Khosla, C., and Omary, M. (2007) Transglutaminase 2 regulates mallory body inclusion formation and injuryassociated liver enlargement, Gastroenterology 132, 1515-1526.
6. Fesus, L., Thomazy, V., and Falus, A. (1987) Induction and activation of tissue transglutaminase during programmed cell death, FEBS Lett. 224, 104-108.
7. De Laurenzi, V. andMelino, G. (2001) Gene disruption of tissue transglutaminase, Mol. Cell Biol. 21, 148-155.
8. Nanda, N., Iismaa, S., Owens, W., Husain, A., Mackay, F., and Graham, R. (2001) Targeted inactivation of Gh/tissue transglutaminase II, J. Biol. Chem. 276, 20673- 20678.
9. Laki, K. and Lóŕand, L. (1948) On the solubility of fibrin clots, Science 108, 280.
10. Fisher, S., Rikover, M., and Naor, S. (1966) Factor 13 deficiency with severe hemorrhagic diathesis, Blood 28, 34-39.
11. Souri, M., Koseki-Kuno, S., Takeda, N., Yamakawa, M., Takeishi, Y., Degen, J., and Ichinose, A. (2008) Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII, Thromb. Haemost. 99, 401-408.
12. Koseki-Kuno, S., Yamakawa, M., Dickneite, G., and Ichinose, A. (2003) Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages, Blood 102, 4410-4412.
13. Williams-Ashman, H., Notides, A., Pabalan, S., and Lorand, L. (1972) Transamidase reactions involved in the enzymic coagulation of semen: isolation of -glutamyl- -lysine dipeptide from clotted secretion protein of guinea pig seminal vesicle, Proc. Natl. Acad. Sci. U.S.A. 69, 2322-2325.
14. Williams-Ashman, H. G. (1984) Transglutaminases and the clotting of mammalian seminal fluids, Mol. Cell Biochem. 58, 51.
15. Matoltsy, A. and Balsamo, C. (1955) A study of the components of the cornified epithelium of human skin, J. Biophys. Biochem. Cytol. 1, 339-360.
16. Brody, I. (1959) An ultrastructural study on the role of the keratohyalin granules in the keratinization process, J. Ultrastruct. Res. 3, 84-104.
17. Matoltsy, A. and Matoltsy, M. (1966) The membrane protein of horny cells, J. Invest. Dermatol. 46, 127-129.
18. Sun, T. andGreen,H. (1976) Differentiation of the epidermal keratinocyte in cell culture: formation of the cornified envelope, Cell 9, 511-521.
19. Rice, R. and Green, H. (1979) Presence in human epidermal cells of a soluble protein precursor of the cross-linked envelope: activation of the cross-linking by calcium ions, Cell 18, 681-694.
20. Rice, R. H. and Green, H. (1977) The cornified envelope of terminally differentiated human epidermal keratinocytes consists of cross-linked protein, Cell 11, 417-422.
21. Rice, R. andGreen,H. (1978) Relation of protein synthesis and transglutaminase activity to formation of the cross-linked envelope during terminal differentiation of the cultured human epidermal keratinocyte, J. Cell Biol. 76, 705-711.
22. Simon, M. andGreen,H. (1985) Enzymatic cross-linking of involucrin and other proteins by keratinocyte particulates in vitro, Cell 40, 677-683.
23. Thacher, S. and Rice, R. (1985) Keratinocyte-specific transglutaminase of cultured human epidermal cells: relation to cross-linked envelope formation and terminal differentiation, Cell 40, 685-695.
24. Phillips, M., Stewart, B., Qin, Q., Chakravarty, R., Floyd, E., Jetten, A., and Rice, R. (1990) Primary structure of keratinocyte transglutaminase, Proc. Natl. Acad. Sci. U.S.A. 87, 9333-9337.
25. Chakravarty, R. and Rice, R. (1989) Acylation of keratinocyte transglutaminase by palmitic and myristic acids in the membrane Anchorage region, J. Biol. Chem. 264, 625-629.
26. Kim, H., Lewis, M., Gorman, J., Park, S., Girard, J., Folk, J., and Chung, S. (1990) Protransglutaminase E from guinea pig skin. Isolation and partial characterization, J. Biol. Chem. 265, 21971-21978.
27. Kim, I., Gorman, J., Park, S., Chung, S., and Steinert, P. (1993) The deduced sequence of the novel protransglutaminase E (TGase3) of human and mouse, J. Biol. Chem. 268, 12682-12690.
28. Hitomi, K., Horio, Y., Ikura, K., Yamanishi, K., and Maki, M. (2001) Analysis of epidermal-type transglutaminase (TGase 3) expression in mouse tissues and cell lines, Int. J. Biochem. Cell Biol. 33, 491-498.
29. Ahvazi, B., Boeshans, K., and Rastinejad, F. (2004) The emerging structural understanding of transglutaminase 3, J. Struct. Biol. 147, 200-207.
30. Hitomi, K., Presland, R., Nakayama, T., Fleckman, P., Dale, B., and Maki, M. (2003) Analysis of epidermal-type transglutaminase (transglutaminase 3) in human stratified epithelia and cultured keratinocytes using monoclonal antibodies, J. Dermatol. Sci. 32, 95-103.
31. Robinson, N., Lapic, S., Welter, J., and Eckert, R. (1997) S100A11, S100A10, annexin I, desmosomal proteins, small proline-rich proteins, plasminogen activator inhibitor-2, and involucrin are components of the cornified envelope of cultured human epidermal keratinocytes, J. Biol. Chem. 272, 12035-12046.
32. Michibata, H., Chiba, H.,Wakimoto, K., Seishima,M., Kawasaki, S., Okubo, K., Mitsui, H., Torii, H., and Imai,Y. (2004) Identification and characterization of a novel component of the cornified envelope, cornifelin, Biochem. Biophys. Res. Commun. 318, 803-813.
33. Steinert, P. and Marekov, L. (1995) The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linkedcomponents of the human epidermal cornified cell envelope, J. Biol. Chem. 270, 17702-17711.
34. Steinert, P. and Marekov, L. (1997) Direct evidence that involucrin is a major early isopeptide cross-linked component of the keratinocyte cornified cell envelope, J. Biol. Chem. 272, 2021-2030.
35. Steinert, P., Kartasova, T., and Marekov, L. (1998) Biochemical evidence that small proline-rich proteins and trichohyalin function in epithelia by modulation of the biomechanical properties of their cornified cell envelopes, J. Biol. Chem. 273, 11758-11769.
36. Simon, M. and Green, H. (1984) Participation of membrane-associated proteins in the formation of the cross-linked envelope of the keratinocyte, Cell 36, 827-834.
37. Ruhrberg, C., Hajibagheri, M., Simon, M., Dooley, T., and Watt, F. (1996) Envoplakin, a novel precursor of the cornified envelope that has homology to desmoplakin, J. Cell Biol. 134, 715-729.
38. Simon, M. and Green, H. (1988) The glutamine residues reactive in transglutaminasecatalyzed cross-linking of involucrin, J. Biol. Chem. 263, 18093-18098.
39. Nemes, Z., Marekov, L., and Steinert, P. (1999) Involucrin cross-linking by transglutaminase Binding to membranes directs residue specificity, J. Biol. Chem. 274, 11013-11021.
40. Marshall, D., Hardman, M., Nield, K., and Byrne, C. (2001) Differentially expressed late constituents of the epidermal cornified envelope, Proc. Natl. Acad. Sci. U.S.A. 98, 13031-13036.
41. Hohl, D., Mehrel, T., Lichti, U., Turner, M., Roop, D., and Steinert, P. (1991) Characterization of human loricrin. Structure and function of a new class of epidermal cell envelope proteins, J. Biol. Chem. 266, 6626-6636.
42. Candi, E., Tarcsa, E., Idler, W., Kartasova, T., Marekov, L., and Steinert, P. (1999) Transglutaminase cross-linking properties of the small proline-rich 1 family of cornified cell envelope proteins. Integration with loricrin, J. Biol. Chem. 274, 7226-7237.
43. Tarcsa, E., Candi, E., Kartasova, T., Idler, W., Marekov, L., and Steinert, P. (1998) Structural and transglutaminase substrate properties of the small proline-rich 2 family of cornified cell envelope proteins, J. Biol. Chem. 273, 23297-23303.
44. Steinert, P., Candi, E., Tarcsa, E., Marekov, L., Sette, M., Paci, M., Ciani, B., Guerrieri, P., and Melino, G. (1999) Transglutaminase crosslinking and structural studies of the human small proline rich 3 protein, Cell Death Differ. 6, 916-930.
45. Park, G., Lim, S., Jang, S., and Morasso, M. (2002) Suprabasin, a novel epidermal differentiation marker and potential cornified envelope precursor, J. Biol. Chem. 277, 45195-45202.
46. Ruse,M., Lambert, A., Robinson, N., Ryan, D., Shon, K., and Eckert, R. (2001) S100A7, S100A10, and S100A11 are transglutaminase substrates, Biochemistry 40, 3167-3173.
47. Robinson, N. and Eckert, R. (1998) Identification of transglutaminase-reactive residues in S100A11, J. Biol. Chem. 273, 2721-2728.
48. Candi, E., Melino, G., Mei, G., Tarcsa, E., Chung, S., Marekov, L., and Steinert, P. (1995) Biochemical, structural, and transglutaminase substrate properties of human loricrin, the major epidermal cornified cell envelope protein, J. Biol. Chem. 270, 26382-26390.
49. Jaskowski, T., Hamblin, T.,Wilson, A., Hill, H., Book, L.,Meyer, L., Zone, J., and Hull, C. (2009) IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease, J. Invest. Dermatol. 129, 2728-2730.
50. Sardy, M., Ḱarpsṕati, S., Merkl, B., Paulsson, M., and Smyth, N. (2002) Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis, J. Exp. Med. 195, 747-757.
51. Donaldson, M., Zone, J., Schmidt, L., Taylor, T., Neuhausen, S., Hull, C., and Meyer, L. (2007) Epidermal transglutaminase deposits in perilesional and uninvolved skin in patients with dermatitis herpetiformis, J. Invest. Dermatol. 127, 1268-1271.
52. Hull, C., Liddle, M., Hansen, N., Meyer, L., Schmidt, L., Taylor, T., Jaskowski, T., Hill, H., and Zone, J. (2008) Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis, Br. J. Dermatol. 159, 120-124.
53. Grenard, P., Bates, M., and Aeschlimann, D. (2001) Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z, J. Biol. Chem.276, 33066-33078.
54. Aeschlimann, D., Koeller, M., Allen-Hoffmann, B., and Mosher, D. (1998) Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes. Detection and identification of transglutaminase gene products based on reverse transcription-polymerase chain reaction with degenerate primers, J. Biol. Chem. 273, 3452-3460.
55. Candi, E., Oddi, S., Paradisi, A., Terrinoni, A., Ranalli, M., Teofoli, P., Citro, G., Scarpato, S., Puddu, P., and Melino, G. (2002) Expression of transglutaminase 5 in normal and pathologic human epidermis, J. Invest. Dermatol. 119, 670-677.
56. Candi, E., Oddi, S.,Terrinoni, A., Paradisi, A., Ranalli, M., Finazzi-Agŕo, A., andMelino, G. (2001) Transglutaminase 5 cross-links loricrin, involucrin, and small proline-rich proteins in vitro, J. Biol. Chem. 276, 35014-35023.
57. Pietroni, V., Di Giorgi, S., Paradisi, A., Ahvazi, B., Candi, E., and Melino, G. (2008) Inactive and highly active, proteolytically processed transglutaminase-5 in epithelial cells, J. Invest. Dermatol.128, 2760-2766.
58. Huber, M., Rettler, I., Bernasconi, K., Frenk, E., Lavrijsen, S., Ponec, M., Bon, A., Lautenschlager, S., Schorderet, D., and Hohl, D. (1995) Mutations of keratinocyte transglutaminase in lamellar ichthyosis, Science 267, 525-528.
59. Russell, L., DiGiovanna, J., Rogers, G., Steinert, P., Hashem, N., Compton, J., and Bale, S. (1995) Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis, Nat. Genet. 9, 279-283.
60. Jeon, S., Djian, P., and Green, H. (1998) Inability of keratinocytes lacking their specific transglutaminase to form cross-linked envelopes: absence of envelopes as a simple diagnostic test for lamellar ichthyosis, Proc. Natl. Acad. Sci. U.S.A. 95, 687-690.
61. Rice, R., Crumrine, D., Hohl, D., Munro, C., and Elias, P. (2003) Cross-linked envelopes in nail plate in lamellar ichthyosis, Br. J. Dermatol. 149, 1050-1054.
62. Matsuki, M., Yamashita, F., Ishida-Yamamoto, A., Yamada, K., Kinoshita, C., Fushiki, S., Ueda, E., Morishima, Y., Tabata, K., Yasuno, H., Hashida, M., Iizuka, H., Ikawa, M., Okabe, M., Kondoh, G., Kinoshita, T., Takeda, J., and Yamanishi, K. (1998) Defectivestratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase). Proc. Natl. Acad. Sci. U.S.A. 95, 1044-1049.
63. Cassidy, A., van Steensel, M., Steijlen, P., van Geel, M., Van Der Velden, J., Morley, S., Terrinoni, A., Melino, G., Candi, E., and McLean, W. (2005) A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome, Am. J. Hum. Genet. 77, 909-917.
64. Watt, F. and Green, H. (1981) Involucrin synthesis is correlated with cell size in human epidermal cultures, J. Cell Biol. 90, 738-742.
65. Watt, F. and Green, H. (1982) Stratification and terminal differentiation of cultured epidermal cells, Nature 295, 434-436.
66. Eckert, R. and Green, H. (1986) Structure and evolution of the human involucrin gene, Cell 46, 583-589.
67. Simon, M., Phillips, M., Green, H., Stroh, H., Glatt, K., Burns, G., and Latt, S. A. (1989) Absence of a single repeat from the coding region of the human involucrin gene leading to RFLP, Am. J. Hum. Genet. 45, 910-916.
68. Simon, M., Phillips, M., and Green, H. (1991) Polymorphism due to variable number of repeats in the human involucrin gene, Genomics 9, 576-580.
69. Djian, P., Delhomme, B., and Green, H. (1995) Origin of the polymorphism of the involucrin gene in Asians, Am. J. Hum. Genet. 56, 1367-1372.
70. Djian, P., Phillips, M., Easley, K., Huang, E., Simon, M., Rice, R., and Green, H. (1993) The involucrin genes of the mouse and the rat: study of their shared repeats, Mol. Biol. Evol. 10, 1136-1149.
71. Djian, P., Easley, K., and Green, H. (2000) Targeted ablation of the murine involucrin gene, J. Cell Biol. 151, 381-388.
72. Vanhoutteghem, A., Djian, P., and Green, H. (2008) Ancient origin of the gene encoding involucrin, a precursor of the cross-linked envelope of epidermis and related epithelia, Proc. Natl. Acad. Sci. U.S.A. 105, 15481-15486.
73. Ruhrberg, C., Hajibagheri, M., Parry, D., and Watt, F. (1997) Periplakin, a novel component of cornified envelopes and desmosomes that belongs to the plakin family and forms complexes with envoplakin, J. Cell Biol. 139, 1835-1849.
74. M̈äatẗa, A., DiColandrea, T.,Groot, K., andWatt, F. (2001) Gene targeting of envoplakin, a cytoskeletal linker protein and precursor of the epidermal cornified envelope, Mol. Cell Biol. 21, 7047-7053.
75. Aho, S., Li, K., Ryoo, Y., McGee, C., Ishida-Yamamoto, A., Uitto, J., and Klement, J. (2004) Periplakin gene targeting reveals a constituent of the cornified cell envelope dispensable for normal mouse development, Mol. Cell Biol. 24, 6410-6418.
76. Sevilla, L., Nachat, R., Groot, K., Klement, J., Uitto, J., Djian, P., M̈äatẗa, A., and Watt, F. (2007) Mice deficient in involucrin, envoplakin, and periplakin have a defective epidermal barrier, J. Cell Biol. 179, 1599-1612.
77. Dale, B., Holbrook, K., and Steinert, P. (1978) Assembly of stratum corneum basic protein and keratin filaments in macrofibrils, Nature 276, 729-731.
78. Kartasova, T. and van de Putte, P. (1988) Isolation, characterization, and UV-stimulated expression of two families of genes encoding polypeptides of related structure in human epidermal keratinocytes, Mol. Cell Biol. 8, 2195-2203.
79. Mehrel, T., Hohl, D., Rothnagel, J., Longley, M., Bundman, D., Cheng, C., Lichti, U., Bisher, M., Steven, A., and Steinert, P. (1990) Identification of a major keratinocyte cell envelope protein, loricrin, Cell 61, 1103-1112.
80. Gan, S., McBride, O., Idler,W., Markova, N., and Steinert, P. (1990) Organization, structure, and polymorphisms of the human profilaggrin gene, Biochemistry 29, 9432-9440.
81. Richards, S., Scott, I.,Harding, C., Liddell, J., Powell, G., and Curtis, C. (1988) Evidence for filaggrin as a component of the cell envelope of the newborn rat, Biochem. J. 253, 153-160.
82. Smith, F., Irvine, A., Terron-Kwiatkowski, A., Sandilands, A., Campbell, L., Zhao, Y., Liao, H., Evans, A., Goudie, D., Lewis-Jones, S., Arseculeratne, G., Munro, C., Sergeant, A., O'Regan, G., Bale, S., Compton, J., DiGiovanna, J., Presland, R., Fleckman, P., and McLean, W. (2006) Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris, Nat. Genet. 38, 337-342.
83. Sandilands, A., Sutherland, C., Irvine, A., and McLean, W. (2009) Filaggrin in the frontline: role in skin barrier function and disease, J. Cell Sci. 122, 1285-1294.
84. Palmer, C., Irvine, A., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S., Goudie, D., Sandilands, A., Campbell, L., Smith, F., O'Regan, G., Watson, R., Cecil, J., Bale, S., Compton, J., DiGiovanna, J., Fleckman, P., Lewis-Jones, S., Arseculeratne, G., Sergeant, A., Munro, C., El Houate, B., McElreavey, K., Halkjaer, L., Bisgaard, H., Mukhopadhyay, S., and McLean, W. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis, Nat. Genet. 38, 441-446.
85. Fallon, P., Sasaki, T., Sandilands, A., Campbell, L., Saunders, S., Mangan, N., Callanan, J., Kawasaki, H., Shiohama, A., Kubo, A., Sundberg, J., Presland, R., Fleckman, P., Shimizu, N., Kudoh, J., Irvine, A., Amagai, M., and McLean,W. (2009) A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming, Nat. Genet. 41, 602-608.
86. Marvin, K., George,M., Fujimoto,W., Saunders, N., Bernacki, S., and Jetten, A. (1992) Cornifin, a cross-linked envelope precursor in keratinocytes that is down-regulated by retinoids, Proc. Natl. Acad. Sci. U.S.A. 89, 11026-11030.
87. Gibbs, S., Fijneman, R., Wiegant, J., van Kessel, A., van De Putte, P., and Backendorf, C. (1993) Molecular characterization and evolution of the SPRR family of keratinocyte differentiation markers encoding small proline-rich proteins, Genomics 16, 630-637.
88. Hohl, D., de Viragh, P., Amiguet-Barras, F., Gibbs, S., Backendorf, C., and Huber, M. (1995) The small proline-rich proteins constitute a multigene family of differentially regulated cornified cell envelope precursor proteins, J. Invest. Dermatol. 104, 902-909.
89. Cabral, A., Sayin, A., de Winter, S., Fischer, D., Pavel, S., and Backendorf, C. (2001) SPRR4, a novel cornified envelope precursor: UV-dependent epidermal expression and selective incorporation into fragile envelopes, J. Cell Sci. 114, 3837-3843.
90. Makino, T., Takaishi, M., Morohashi, M., and Huh, N. (2001) Hornerin, a novel profilaggrin-like protein and differentiation-specific marker isolated from mouse skin, J. Biol. Chem. 276, 47445-47452.
91. Makino, T., Takaishi, M., Toyoda, M., Morohashi, M., and Huh, N. (2003) Expression of hornerin in stratified squamous epithelium in the mouse: a comparative analysis with profilaggrin, J. Histochem. Cytochem. 51, 485-492.
92. Takaishi, M., Makino, T., Morohashi, M., and Huh, N. (2005) Identification of human hornerin and its expression in regenerating and psoriatic skin, J. Biol. Chem. 280, 4696-4703.
93. Wu, Z., Meyer-Hoffert, U., Reithmayer, K., Paus, R., Hansmann, B., He, Y., Bartels, J., Gl̈aser, R., Harder, J., and Schr̈oder, J. (2009) Highly complex peptide aggregates of the S100 fused-type protein hornerin are present in human skin, J. Invest. Dermatol. 129, 1446-1458.
94. Koch, P., deViragh, P., Scharer, E., Bundman, D., Longley,M., Bickenbach, J., Kawachi, Y., Suga, Y., Zhou, Z., Huber, M., Hohl, D., Kartasova, T., Jarnik, M., Steven, A., and Roop, D. (2000) Lessons from loricrin-deficient mice: compensatory mechanisms maintaining skin barrier function in the absence of a major cornified envelope protein, J. Cell Biol. 151, 389-400.
95. Jarnik, M., de Viragh, P., Scḧarer, E., Bundman, D., Simon, M., Roop, D., and Steven, A. (2002) Quasi-normal cornified cell envelopes in loricrin knockout mice imply the existence of a loricrin backup system, J. Invest. Dermatol. 118, 102-109.
96. Maestrini, E., Monaco, A., McGrath, J., Ishida-Yamamoto, A., Camisa, C., Hovnanian, A., Weeks, D., Lathrop, M., Uitto, J., and Christiano, A. (1996) A molecular defect in loricrin, the major component of the cornified cell envelope, underlies Vohwinkel's syndrome, Nat. Genet. 13, 70-77.
97. Suga,Y., Jarnik,M., Attar, P., Longley,M., Bundman, D., Steven, A.,Koch, P., and Roop, D. (2000) Transgenic mice expressing a mutant form of loricrin reveal the molecular basis of the skin diseases, Vohwinkel syndrome and progressive symmetric erythrokeratoderma, J. Cell Biol. 151, 401-412.
98. de Cid, R., Riveira-Munoz, E., Zeeuwen, P., Robarge, J., Liao,W., Dannhauser, E., Giardina, E., Stuart, P., Nair, R., Helms, C., Escaraḿis, G., Ballana, E.,Mart́in-Ezquerra, G., den Heijer, M., Kamsteeg, M., Joosten, I., Eichler, E., Ĺazaro, C., Pujol, R., Armengol, L., Abecasis, G., Elder, J., Novelli, G., Armour, J., Kwok, P., Bowcock, A., Schalkwijk, J., and Estivill, X. (2009) Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis, Nat. Genet. 41, 211-215.
99. Mischke, D., Korge, B., Marenholz, I., Volz, A., and Ziegler, A. (1996) Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex (" epidermal differentiation complex" ) on human chromosome 1q21, J. Invest. Dermatol. 106, 989-992.
100. McKinley-Grant, L., Idler,W., Bernstein, I., Parry, D., Cannizzaro, L., Croce, C., Huebner, K., Lessin, S., and Steinert, P. (1989) Characterization of a cDNA clone encoding human filaggrin and localization of the gene to chromosome region 1q21, Proc. Natl. Acad. Sci. U.S.A. 86, 4848-4852.
101. Rothnagel, J. and Rogers, G. (1986) Trichohyalin, an intermediate filament-associated protein of the hair follicle, J. Cell Biol. 102, 1419-1429.
102. Yoneda, K., Hohl, D., McBride, O., Wang, M., Cehrs, K., Idler, W., and Steinert, P. (1992) The human loricrin gene, J. Biol. Chem. 267, 18060-18066.
103. Volz, A., Korge, B., Compton, J., Ziegler, A., Steinert, P., and Mischke, D. (1993) Physical mapping of a functional cluster of epidermal differentiation genes on chromosome 1q21, Genomics 18, 92-99.
104. Contzler, R., Favre, B., Huber, M., and Hohl, D. (2005) Cornulin, a new member of the " fused gene" family, is expressed during epidermal differentiation, J. Invest. Dermatol. 124, 990-997.
105. Huber, M., Siegenthaler, G., Mirancea, N., Marenholz, I., Nizetic, D., Breitkreutz, D., Mischke, D., and Hohl, D. (2005) Isolation and characterization of human repetin, a member of the fused gene family of the epidermal differentiation complex, J. Invest. Dermatol. 124, 998-1007.
106. Green, H., and Djian, P. (1992) Consecutive actions of different gene-altering mechanisms in the evolution of involucrin, Mol. Biol. Evol. 9, 977-1017.
107. Backendorf, C., and Hohl, D. (1992) A common origin for cornified envelope proteins? Nat. Genet. 2, 91.
108. South, A., Cabral, A., Ives, J., James, C., Mirza, G., Marenholz, I., Mischke, D., Backendorf, C., Ragoussis, J., and Nizetic, D. (1999) Human epidermal differentiation complex in a single 2.5 Mbp long continuum of overlapping DNA cloned in bacteria integrating physical and transcript maps, J. Invest. Dermatol. 112, 910-918.
109. Sotiropoulou, G., Anisowicz, A., and Sager, R. (1997) Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer, J. Biol. Chem. 272, 903-910.
110. Ni, J., Abrahamson, M., Zhang, M., Fernandez, M., Grubb, A., Su, J., Yu, G., Li, Y., Parmelee, D., Xing, L., Coleman, T., Gentz, S., Thotakura, R., Nguyen, N., Hesselberg, M., and Gentz, R. (1997) Cystatin E is a novel human cysteine proteinase inhibitor with structural resemblance to family 2 cystatins, J. Biol. Chem. 272, 10853-10858.
111. Zeeuwen, P., van Vlijmen-Willems, I., Hendriks, W., Merkx, G., and Schalkwijk, J. (2002) A null mutation in the cystatin M/E gene of ichq mice causes juvenile lethality and defects in epidermal cornification, Hum. Mol. Genet. 11, 2867-2875.
112. Zeeuwen, P., van Vlijmen-Willems, I., Olthuis, D., Johansen, H., Hitomi, K., Hara-Nishimura, I., Powers, J., James, K., op den Camp, H., Lemmens, R., and Schalkwijk, J. (2004) Evidence that unrestricted legumain activity is involved in disturbed epidermal cornification in cystatin M/E deficient mice, Hum. Mol. Genet. 13, 1069- 1079.
113. Zeeuwen, P., Van Vlijmen-Willems, I., Jansen, B., Sotiropoulou, G., Curfs, J., Meis, J., Janssen, J., Van Ruissen, F., and Schalkwijk, J. (2001) Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands: a new skinspecific proteinase inhibitor that is a target for cross-linking by transglutaminase, J. Invest. Dermatol. 116, 693-701.
114. Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A., Bonaf́e, J., Wilkinson, J., Täieb, A., Barrandon, Y., Harper, J., de Prost, Y., and Hovnanian, A. (2000) Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome, Nat. Genet. 25, 141-142.
115. Toomes, C., James, J., Wood, A., Wu, C., McCormick, D., Lench, N., Hewitt, C., Moynihan, L., Roberts, E., Woods, C., Markham, A., Wong, M., Widmer, R., Ghaffar, K., Pemberton, M., Hussein, I., Temtamy, S., Davies, R., Read, A., Sloan, P., Dixon, M., and Thakker, N. (1999) Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis, Nat. Genet. 23, 421-424.
116. Roth,W., Deussing, J., Botchkarev, V., Pauly-Evers,M., Saftig, P., Hafner, A., Schmidt, P., Schmahl, W., Scherer, J., Anton-Lamprecht, I., Von Figura, K., Paus, R., and Peters, C. (2000) Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling, FASEB J. 14, 2075-2086.
117. Zeeuwen, P., Dale, B., de Jongh, G., van Vlijmen-Willems, I., Fleckman, P., Kimball, J., Stephens, K., and Schalkwijk, J. (2003) The human cystatin M/E gene (CST6): exclusion candidate gene for harlequin ichthyosis, J. Invest. Dermatol. 121, 65-68.
118. Thomas, A., Cullup, T., Norgett, E., Hill, T., Barton, S., Dale, B., Sprecher, E., Sheridan, E., Taylor, A., Wilroy, R., DeLozier, C., Burrows, N., Goodyear, H., Fleckman, P., Stephens, K., Mehta, L., Watson, R., Graham, R., Wolf, R., Slavotinek, A., Martin, M., Bourn, D., Mein, C., O'Toole, E., and Kelsell, D. (2006) ABCA12 is themajor harlequin ichthyosis gene, J. Invest. Dermatol. 126, 2408-2413.
119. Candi, E., Tarcsa, E., Digiovanna, J., Compton, J., Elias, P., Marekov, L., and Steinert, P. (1998) A highly conserved lysine residue on the head domain of type II keratins is essential for the attachment of keratin intermediate filaments to the cornified cell envelope through isopeptide crosslinking by transglutaminases, Proc. Natl. Acad. Sci. U.S.A. 95, 2067-2072.
120. Djian, P. and Green, H. (1989) The involucrin gene of the orangutan: generation of the late region as an evolutionary trend in the hominoids, Mol. Biol. Evol. 6, 469-477.
121. Phillips, M., Djian, P., and Green, H. (1990) The involucrin gene of the galago. Existence of a correction process acting on its segment of repeats, J. Biol. Chem. 265, 7804-7807.
122. Djian, P. and Green, H. (1991) Involucrin gene of tarsioids and other primates: alternatives in evolution of the segment of repeats, Proc. Natl. Acad. Sci. U.S.A. 88, 5321-5325.
123. La Spada, A.,Wilson, E., Lubahn, D., Harding, A., and Fischbeck, K. (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy, Nature 352, 77-79.
124. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes, Cell 72, 971-983.
125. Green, H. (1993) Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism, Cell 74, 955-956.
126. Davies, S., Turmaine, M., Cozens, B., DiFiglia, M., Sharp, A., Ross, C., Scherzinger, E.,Wanker, E.,Mangiarini, L., and Bates, G. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for theHDmutation, Cell 90, 537-548.
127. DiFiglia, M., Sapp, E., Chase, K., Davies, S., Bates, G., Vonsattel, J., and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain, Science 277, 1990-1993.
128. Selkoe, D., Ihara, Y., and Salazar, F. (1982) Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea, Science 215, 1243-1245.
129. Junn, E., Ronchetti, R., Quezado, M., Kim, S., and Mouradian, M. (2003) Tissue transglutaminase-induced aggregation of α-synuclein: implications for Lewy bodyformation in Parkinson's disease and dementia with Lewy bodies, Proc. Natl. Acad. Sci. U.S.A. 100, 2047-2052.
130. Gilad, G. and Varon, L. (1985) Transglutaminase activity in rat brain: characterization, distribution, and changes with age, J. Neurochem. 45, 1522-1526.
131. Kim, S., Grant, P., Lee, J., Pant, H., and Steinert, P. (1999) Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease, J. Biol. Chem. 274, 30715-30721.
132. Lesort, M., Attanavanich, K., Zhang, J., and Johnson, G. (1998) Distinct nuclear localization and activity of tissue transglutaminase, J. Biol. Chem. 273, 11991-11994.
133. Dedeoglu, A.,Kubilus, J., Jeitner, T., Matson, S., Bogdanov, M.,Kowall, N., Matson,W., Cooper, A., Ratan, R., Beal, M., Hersch, S., and Ferrante, R. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease, J. Neurosci. 22, 8942-8950.
134. Hoffner, G., Van Der Rest, G., Dansette, P., and Djian, P. (2009) The end product of transglutaminase crosslinking: simultaneous quantitation of [Nε-(γ-glutamyl) lysine] and lysine by HPLC-MS3, Anal. Biochem. 384, 296-304.
135. Simon, S. and Llińas, R. (1985) Compartmentalization of the submembrane calcium activity during calcium influx and its significance in transmitter release, Biophys. J. 48, 485-498.
136. Yamada, W. and Zucker, R. (1992) Time course of transmitter release calculated from simulations of a calcium diffusion model, Biophys. J. 61, 671-682.
137. Neher, E. (1998) Vesicle pools and Ca2+ microdomains: new tools for understanding their roles in neurotransmitter release, Neuron 20, 389-399.
138. Stern, M. (1992) Buffering of calcium in the vicinity of a channel pore, Cell Calcium 13, 183-192.
139. Zainelli, G., Ross, C., Troncoso, J., Fitzgerald, J., and Muma, N. (2004) Calmodulin regulates transglutaminase 2 cross-linking of huntingtin, J. Neurosci. 24, 1954-1961.
140. Monsonego, A., Shani, Y., Friedmann, I., Paas, Y., Eizenberg, O., and Schwartz, M. (1997) Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes, J. Biol. Chem. 272, 3724-3732.
141. Monsonego, A., Friedmann, I., Shani, Y., Eisenstein,M., and Schwartz, M. (1998) GTPdependent conformational changes associated with the functional switch between Gα and cross-linking activities in brain-derived tissue transglutaminase, J. Mol. Biol. 282, 713-720.
142. Citron, B., SantaCruz, K., Davies, P., and Festoff, B. (2001) Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease, J. Biol. Chem. 276, 3295-3301.
143. Nasir, J., Floresco, S., O'Kusky, J., Diewert, V., Richman, J., Zeisler, J., Borowski, A., Marth, J., Phillips, A., and Hayden, M. (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes, Cell 81, 811-823.
144. Kahlem, P., Green, H., and Djian, P. (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine, Mol. Cell 1, 595-601.
145. Karpuj, M., Garren, H., Slunt, H., Price, D., Gusella, J., Becher, M., and Steinman, L. (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei, Proc. Natl. Acad. Sci. U.S.A. 96, 7388-7393.
146. Zainelli, G., Dudek, N., Ross, C., Kim, S., and Muma, N. (2005) Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3, J. Neuropathol. Exp. Neurol. 64, 58-65.
147. Zainelli, G., Ross, C., Troncoso, J., and Muma, N. (2003) Transglutaminase cross-links in intranuclear inclusions in Huntington disease, J. Neuropathol. Exp. Neurol. 62, 14-24.
148. Matilla, A., Roberson, E., Banfi, S., Morales, J., Armstrong, D., Burright, E., Orr, H., Sweatt, J., Zoghbi, H., and Matzuk, M. (1998) Mice lacking ataxin-1 display learning deficits and decreased hippocampal paired-pulse facilitation, J. Neurosci. 18, 5508-5516.
149. Kahlem, P., Terŕe, C., Green, H., and Djian, P. (1996) Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system, Proc. Natl. Acad. Sci. U.S.A. 93, 14580-14585.
150. D'Souza, D., Wei, J., Shao, Q., Hebert, M., Subramony, S., and Vig, P. (2006) Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis, Neurosci. Lett. 409, 5-9.
151. Kiehl, T., Nechiporuk, A., Figueroa, K., Keating, M., Huynh, D., and Pulst, S. (2006) Generation and characterization of Sca2 (ataxin-2) knockout mice, Biochem. Biophys. Res. Commun. 339, 17-24.
152. Schmitt, I., Linden, M.,Khazneh, H., Evert, B.,Breuer, P.,Klockgether, T., andWuellner, U. (2007) Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination, Biochem. Biophys. Res. Commun. 362, 734-739.
153. Zhuchenko, O., Bailey, J., Bonnen, P., Ashizawa, T., Stockton, D., Amos, C., Dobyns, W., Subramony, S., Zoghbi, H., and Lee, C. (1997) Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α 1A-voltage-dependent calcium channel, Nat. Genet. 15, 62-69.
154. Jun, K., Piedras-Renteŕia, E., Smith, S., Wheeler, D., Lee, S., Lee, T., Chin, H., Adams, M., Scheller, R., Tsien, R., and Shin, H. (1999) Ablation of P/Q-type Ca(2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the α(1A)-subunit, Proc. Natl. Acad. Sci. U.S.A. 96, 15245-15250.
155. Helmlinger, D., Hardy, S., Sasorith, S., Klein, F., Robert, F., Weber, C., Miguet, L., Potier, N., Van-Dorsselaer, A., Wurtz, J., Mandel, J., Tora, L., and Devys, D. (2004) Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes, Hum. Mol. Genet. 13, 1257-1265.
156. Koide, R., Kobayashi, S., Shimohata, T., Ikeuchi, T., Maruyama,M., Saito,M., Yamada, M., Takahashi, H., and Tsuji, S. (1999) A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum. Mol. Genet. 8, 2047-2053.
157. Mandrusiak, L., Beitel, L., Wang, X., Scanlon, T., Chevalier-Larsen, E., Merry, D., and Trifiro, M. (2003) Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor, Hum. Mol. Genet. 12, 1497-1506.
158. Shen,Y., Lee, G., Choe,Y., Zoltewicz, J., and Peterson, A. (2007) Functional architecture of atrophins, J. Biol. Chem. 282, 5037-5044.
159. Koide, R., Ikeuchi, T., Onodera, O., Tanaka, H., Igarashi, S., Endo, K., Takahashi, H., Kondo, R., Ishikawa, A., and Hayashi, T. (1994) Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat. Genet. 6, 9-13.
160. Orr, H., Chung, M., Banfi, S., Kwiatkowski, T. J., Servadio, A., Beaudet, A., McCall, A., Duvick, L., Ranum, L., and Zoghbi, H. (1993) Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1, Nat. Genet. 4, 221-226.
161. Sanpei, K., Takano, H., Igarashi, S., Sato, T., Oyake, M., Sasaki, H., Wakisaka, A., Tashiro, K., Ishida, Y., Ikeuchi, T., Koide, R., Saito, M., Sato, A., Tanaka, T., Hanyu, S., Takiyama, Y., Nishizawa, M., Shimizu, N., Nomura, Y., Segawa, M., Iwabuchi, K., Eguchi, I., Tanaka, H., Takahashi, H., and Tsuji, S. (1996) Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT, Nat. Genet. 14, 277-284.
162. Pulst, S., Nechiporuk, A., Nechiporuk, T., Gispert, S., Chen, X., Lopes-Cendes, I., Pearlman, S., Starkman, S., Orozco-Diaz, G., Lunkes, A., DeJong, P., Rouleau, G., Auburger, G., Korenberg, J., Figueroa, C., and Sahba, S. (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2, Nat. Genet. 14, 269-276.
163. Imbert, G., Saudou, F., Yvert, G., Devys, D., Trottier, Y., Garnier, J.,Weber, C.,Mandel, J., Cancel, G., Abbas, N., D̈urr, A., Didierjean, O., Stevanin, G., Agid, Y., and Brice, A. (1996) Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats, Nat. Genet. 14, 285-291.
164. Kawaguchi, Y., Okamoto, T., Taniwaki, M., Aizawa, M., Inoue, M., Katayama, S., Kawakami, H., Nakamura, S., Nishimura, M., and Akiguchi, I. (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1, Nat. Genet. 8, 221-228.
165. David, G., Abbas, N., Stevanin, G., D̈urr, A., Yvert, G., Cancel, G., Weber, C., Imbert, G., Saudou, F., Antoniou, E., Drabkin, H., Gemmill, R., Giunti, P., Benomar, A.,Wood, N., Ruberg, M., Agid, Y., Mandel, J., and Brice, A. (1997) Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion, Nat. Genet. 17, 65-70.
166. Zuhlke, C., Hellenbroich, Y., Dalski, A., Kononowa, N., Hagenah, J., Vieregge, P., Riess, O., Klein, C., and Schwinger, E. (2001) Different types of repeat expansion in the TATAbinding protein gene are associated with a new form of inherited ataxia, Eur. J. Hum. Genet. 9, 160-164.
167. Djian, P. (1998) Evolution of simple repeats in DNA and their relation to human disease, Cell 94, 155-160.
168. Hoffner, G. and Djian, P. (2005) Transglutaminase and diseases of the central nervous system, Front. Biosci. 10, 3078-3092.
169. Ordway, J., Tallaksen-Greene, S., Gutekunst, C., Bernstein, E., Cearley, J., Wiener, H., Dure, L. T., Lindsey, R., Hersch, S., Jope, R., Albin, R., and Detloff, P. (1997) Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse, Cell 91, 753-763.
170. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S., and Bates, G. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell 87, 493-506.
171. Vonsattel, J., Myers, R., Stevens, T., Ferrante, R., Bird, E., and Richardson, E. J. (1985) Neuropathological classification of Huntington's disease, J. Neuropathol. Exp. Neurol. 44, 559-577.
172. Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S., and Kakizuka, A. (1996) Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo, Nat. Genet. 13, 196-202.
173. Warrick, J., Paulson, H., Gray-Board, G., Bui, Q., Fischbeck, K., Pittman, R., and Bonini, N. (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila, Cell 93, 939-949.
174. Tellez-Nagel, I., Johnson, A., and Terry, R. (1974) Studies on brain biopsies of patients with Huntington's chorea, J. Neuropathol. Exp. Neurol. 33, 308-332.
175. Subramaniam, S., Sixt, K., Barrow, R., and Snyder, S. (2009) Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity, Science 324, 1327-1330.
176. Paulson, H., Perez, M., Trottier, Y., Trojanowski, J., Subramony, S., Das, S., Vig, P., Mandel, J., Fischbeck, K., and Pittman, R. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3, Neuron 19, 333-344.
177. Skinner, P., Koshy, B., Cummings, C., Klement, I., Helin, K., Servadio, A., Zoghbi, H., and Orr, H. (1997) Ataxin-1 with an expanded glutamine tract alters nuclear matrixassociated structures, Nature 389, 971-974.
178. Hayashi, Y., Kakita, A., Yamada, M., Koide, R., Igarashi, S., Takano, H., Ikeuchi, T., Wakabayashi, K., Egawa, S., Tsuji, S., and Takahashi, H. (1998) Hereditary dentatorubral-pallidoluysian atrophy: detection of widespread ubiquitinated neuronal and glial intranuclear inclusions in the brain, Acta Neuropathol. 96, 547- 552.
179. Holmberg, M., Duyckaerts, C., Dürr, A., Cancel, G., Gourfinkel-An, I., Damier, P., Faucheux, B., Trottier, Y., Hirsch, E., Agid, Y., and Brice, A. (1998) Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions, Hum. Mol. Genet. 7, 913-918.
180. Ishikawa, K., Fujigasaki, H., Saegusa, H., Ohwada, K., Fujita, T., Iwamoto, H., Komatsuzaki, Y., Toru, S., Toriyama, H., Watanabe, M., Ohkoshi, N., Shoji, S., Kanazawa, I., Tanabe, T., andMizusawa,H. (1999) Abundant expression and cytoplasmic aggregations of [α]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6, Hum. Mol. Genet. 8, 1185-1193.
181. Koyano, S., Uchihara, T., Fujigasaki, H., Nakamura, A., Yagishita, S., and Iwabuchi, K. (1999) Neuronal intranuclear inclusions in spinocerebellar ataxia type 2: triple-labeling immunofluorescent study, Neurosci. Lett. 273, 117-120.
182. Nakamura, K., Jeong, S., Uchihara, T., Anno, M., Nagashima, K., Nagashima, T., Ikeda, S., Tsuji, S., and Kanazawa, I. (2001) SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein, Hum. Mol. Genet. 10, 1441-1448.
183. Fujigasaki, H., Martin, J., De Deyn, P., Camuzat, A., Deffond, D., Stevanin, G., Dermaut, B., Van Broeckhoven, C., D̈urr, A., and Brice, A. (2001) CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia, Brain 124, 1939-1947.
184. Hoffner, G., Island, M., and Djian, P. (2005) Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers, J. Neurochem. 95, 125-136.
185. Becher, M., Kotzuk, J., Sharp, A., Davies, S., Bates, G., Price, D., and Ross, C. (1998) Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length, Neurobiol. Dis. 4, 387-397.
186. Sieradzan, K., Mechan, A., Jones, L., Wanker, E., Nukina, N., and Mann, D. (1999) Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein, Exp. Neurol. 156, 92-99.
187. Gutekunst, C., Li, S., Yi, H., Mulroy, J., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R., Hersch, S., and Li, X. (1999) Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology, J. Neurosci. 19, 2522-2534.
188. Iuchi, S., Hoffner, G., Verbeke, P., Djian, P., and Green, H. (2003) Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine, Proc. Natl. Acad. Sci. U.S.A. 100, 2409-2414.
189. Kahlem, P. and Djian, P. (2000) The expanded CAG repeat associated with juvenile Huntington disease shows a common origin of most or all neurons and glia in human cerebrum, Neurosci. Lett. 286, 203-207.
190. Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G., Davies, S., Lehrach, H., and Wanker, E. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo, Cell 90, 549-558.
191. Yang,W.,Dunlap, J., Andrews, R., andWetzel, R. (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells, Hum. Mol. Genet. 11, 2905-2917.
192. Li, H., Li, S., Yu, Z., Shelbourne, P., and Li, X. (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice, J. Neurosci. 21, 8473-8481.
193. Carmichael, J., Chatellier, J.,Woolfson, A., Milstein, C., Fersht, A., and Rubinsztein, D. (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease, Proc. Natl. Acad. Sci. U.S.A. 97, 9701-9705.
194. Kitamura, A.,Kubota, H., Pack,C., Matsumoto, G., Hirayama, S., Takahashi,Y.,Kimura, H., Kinjo, M., Morimoto, R., and Nagata, K. (2006) Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state, Nat. Cell Biol. 8, 1163-1170.
195. Iwata, A., Nagashima, Y.,Matsumoto, L., Suzuki, T., Yamanaka, T., Date, H., Deoka, K., Nukina, N., and Tsuji, S. (2009) Intranuclear degradation of polyglutamine aggregates by the ubiquitin-proteasome system, J. Biol. Chem. 284, 9796-9803.
196. Palazzolo, I., Stack, C., Kong, L., Musaro, A., Adachi, H., Katsuno, M., Sobue, G., Taylor, J., Sumner, C., Fischbeck, K., and Pennuto, M. (2009) Overexpression of IGF-1in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy, Neuron 63, 316-328.
197. Wang, H., Xu, Y., Zhao, X., Zhao, H., Yan, J., Sun, X., Guo, J., and Zhu, C. (2009) Overexpression of F(0)F(1)-ATP synthase suppresses mutant huntingtin aggregation and toxicity in vitro, Biochem. Biophys. Res. Commun. 390, 1294-1298.
198. Wang, C., Zhou, H., McGuire, J., Cerullo, V., Lee, B., Li, S., and Li, X. (2008) Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin, J. Cell Biol. 181, 803-816.
199. Sanchez, I.,Mahlke, C., and Yuan, J. (2003) Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders, Nature 421, 373-379.
200. Kazantsev, A., Walker, H., Slepko, N., Bear, J., Preisinger, E., Steffan, J., Zhu, Y., Gertler, F., Housman, D., Marsh, J., and Thompson, L. (2002) A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila, Nat. Genet. 30, 367-376.
201. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions, Cell 95, 55-66.
202. Arrasate, M., Mitra, S., Schweitzer, E., Segal, M., and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death, Nature 431, 805-810.
203. Uchihara, T., Iwabuchi, K., Funata, N., and Yagishita, S. (2002) Attenuated nuclear shrinkage in neurons with nuclear aggregates-a morphometric study on pontine neurons of Machado-Joseph disease brains, Exp. Neurol. 178, 124-128.
204. Nagaoka, U., Uchihara, T., Iwabuchi, K., Konno, H., Tobita, M., Funata, N., Yagishita, S., and Kato, T. (2003) Attenuated nuclear shrinkage in neurones with nuclear inclusions of SCA1 brains, J. Neurol. Neurosurg. Psychiatry 74, 597-601.
205. Ross, C., and Poirier, M. (2004) Protein aggregation and neurodegenerative disease, Nat. Med. 10(Suppl), S10-S17.
206. Steffan, J., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L., Slepko, N., Illes, K., Lukacsovich, T., Zhu, Y., Cattaneo, E., Pandolfi, P., Thompson, L., and Marsh, J. (2004) SUMO modification of Huntingtin and Huntington's disease pathology, Science 304, 100-104.
207. Perutz, M., Johnson, T., Suzuki, M., and Finch, J. (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases, Proc. Natl. Acad. Sci. U.S.A. 91, 5355-5358.
208. Perutz, M. (1996) Glutamine repeats and inherited neurodegenerative diseases: molecular aspects, Curr. Opin. Struct. Biol. 6, 848-858.
209. Stott, K., Blackburn, J., Butler, P., and Perutz, M. (1995) Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases, Proc. Natl. Acad. Sci. U.S.A. 92, 6509-6513.
210. Hazeki, N., Tukamoto, T., Goto, J., and Kanazawa, I. (2000) Formic acid dissolves aggregates of an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying to quantification of protein components of the aggregates, Biochem. Biophys. Res. Commun. 277, 386-393.
211. Lin, C., Tallaksen-Greene, S., Chien, W., Cearley, J., Jackson, W., Crouse, A., Ren, S., Li, X., Albin, R., and Detloff, P. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease, Hum. Mol. Genet. 10, 137-144.
212. Zhou, H., Cao, F., Wang, Z., Yu, Z., Nguyen, H., Evans, J., Li, S., and Li, X. (2003) Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity, J. Cell Biol. 163, 109-118.
213. Cooper, A. J., Sheu, K. F., Burke, J. R., Onodera, O., Strittmatter, W. J., Roses, A. D., and Blass, J. P. (1997) Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases? J. Neurochem. 69, 431-434.
214. Gentile, V., Sepe, C., Calvani, M.,Melone,M. A., Cotrufo, R., Cooper, A. J., Blass, J. P., and Peluso, G. (1998) Tissue transglutaminase-catalyzed formation of high-molecularweight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing toCAG-triplet diseases, Arch. Biochem. Biophys. 352, 314-321.
215. Igarashi, S., Koide, R., Shimohata, T., Yamada, M., Hayashi, Y., Takano, H., Date, H., Oyake, M., Sato, T., Sato, A., Egawa, S., Ikeuchi, T., Tanaka, H., Nakano, R., Tanaka, K., Hozumi, I., Inuzuka, T., Takahashi, H., and Tsuji, S. (1998) Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch, Nat. Genet. 18, 111-117.
216. de Cristofaro, T., Affaitati, A., Cariello, L., Avvedimento, E., and Varrone, S. (1999) The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates, Biochem. Biophys. Res. Commun. 260, 150-158.
217. Mastroberardino, P., Iannicola, C.,Nardacci, R., Bernassola, F.,De Laurenzi,V.,Melino, G., Moreno, S., Pavone, F., Oliverio, S., Fesus, L., and Piacentini, M. (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease, Cell Death Differ. 9, 873-880.
218. Bailey, C. and Johnson, G. (2005) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms, J. Neurochem. 92, 83-92.
219. Lai, T., Tucker, T., Burke, J., Strittmatter, W., and Greenberg, C. (2004) Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats, J. Neurochem. 88, 1253-1260.
220. Karpuj, M., Becher, M., Springer, J., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D., and Steinman, L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine, Nat. Med. 8, 143-149.
221. Wang, X., Sarkar, A., Cicchetti, F., Yu, M., Zhu, A., Jokivarsi, K., Saint-Pierre, M., and Brownell, A. (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease, J. Neurol. Sci. 231, 57-66.
222. Van Raamsdonk, J., Pearson, J., Bailey, C., Rogers, D., Johnson, G., Hayden, M., and Leavitt, B. (2005) Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease, J. Neurochem. 95, 210-220.
223. Chun, W., Lesort, M., Tucholski, J., Ross, C., and Johnson, G. (2001) Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates, J. Cell Biol. 153, 25-34.
224. Tucholski, J., Lesort, M., and Johnson, G. (2001) Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells, Neuroscience 102, 481-491.
225. Bailey, C. and Johnson, G. (2006) The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase, Neurobiol. Aging 27, 871-879.
226. Jeitner, T., Bogdanov, M., Matson, W., Daikhin, Y., Yudkoff, M., Folk, J., Steinman, L., Browne, S., Beal, M., Blass, J., and Cooper, A. (2001) N(ε)-(γ-L-glutamyl)-Llysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease, J. Neurochem. 79, 1109-1112.
227. Johnson, G. and LeShoure, R. J. (2004) Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the ε-(γ-glutamyl)lysine bonds formed by transglutaminase activity, J. Neurosci. Methods 134, 151-158.
228. Lesort, M., Chun, W., Johnson, G., and Ferrante, R. (1999) Tissue transglutaminase is increased in Huntington's disease brain, J. Neurochem. 73, 2018-2027.
229. Cariello, L., de Cristofaro, T., Zanetti, L., Cuomo, T., Di Maio, L., Campanella, G., Rinaldi, S., Zanetti, P., Di Lauro, R., and Varrone, S. (1996) Transglutaminase activity is related to CAG repeat length in patients with Huntington's disease, Hum. Genet. 98, 633-635.
230. Hoffner, G. and Djian, P. (2002) Protein aggregation in Huntington's disease, Biochimie 84, 273-278.
231. Hoffner, G., Hoppilliard, Y., Van Der Rest, G., Dansette, P., Djian, P., and Ohanessian, G. (2008) [Nε-(γ-glutamyl) lysine] as a potential biomarker in neurological diseases: new detection method and fragmentation pathways, J. Mass Spectrom. 43, 456- 469.
232. Selkoe, D., Abraham, C., and Ihara, Y. (1982) Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers, Proc. Natl. Acad. Sci. U.S.A. 79, 6070-6074.
233. Lee, V., Balin, B., Otvos, L. J., and Trojanowski, J. (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau, Science 251, 675- 678.
234. Goedert, M., Spillantini, M., Cairns, N., and Crowther, R. (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms, Neuron 8, 159-168.
235. Dudek, S. and Johnson, G. (1993) Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau, J. Neurochem. 61, 1159-1162.
236. Dudek, S. and Johnson, G. (1994) Transglutaminase facilitates the formation of polymers of the amyloid peptide, Brain Res. 651, 129-133.
237. Miller, M. and Johnson, G. (1995) Transglutaminase cross-linking of the tau protein, J. Neurochem. 65, 1760-1770.
238. Appelt, D. and Balin, B. (1997) The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures, Brain Res. 745, 21-31.
239. Halverson, R., Lewis, J., Frausto, S., Hutton, M., and Muma, N. (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice, J. Neurosci. 25, 1226-1233.
240. Appelt, D., Kopen, G., Boyne, L., and Balin, B. (1996) Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease, J. Histochem. Cytochem. 44, 1421-1427.
241. Wilhelmus, M., Grunberg, S., Bol, J., van Dam, A., Hoozemans, J., Rozemuller, A., and Drukarch, B. (2009) Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain, Brain Pathol. 19, 612-622.
242. Gorevic, P., Go{ogonek}ni, F., Pons-Estel, B., Alvarez, F., Peress, N., and Frangione, B. (1986) Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: immunohistological studies, J. Neuropathol. Exp. Neurol. 45, 647-664.
243. Selkoe, D., Abraham, C., Podlisny,M., and Duffy, L. (1986) Isolation of low-molecularweight proteins from amyloid plaque fibers in Alzheimer's disease, J. Neurochem. 46, 1820-1834.
244. Ikura, K., Takahata, K., and Sasaki, R. (1993) Cross-linking of a synthetic partial-length (1-28) peptide of the Alzheimer β/A4 amyloid protein by transglutaminase, FEBS Lett. 326, 109-111.
245. Ho, G., Gregory, E., Smirnova, I., Zoubine, M., and Festoff, B. (1994) Cross-linking of β-amyloid protein precursor catalyzed by tissue transglutaminase, FEBS Lett. 349, 151-154.
246. Rasmussen, L., Sørensen, E., Petersen, T., Gliemann, J., and Jensen, P. (1994) Identification of glutamine and lysine residues in Alzheimer amyloid β A4 peptide responsible for transglutaminase-catalysed homopolymerization and cross-linking to β 2M receptor, FEBS Lett. 338, 161-166.
247. Hartley, D., Zhao, C., Speier, A.,Woodard, G., Li, S., Li, Z., andWalz, T. (2008) Transglutaminase induces protofibril-like amyloid β-protein assemblies that are proteaseresistant and inhibit long-term potentiation, J. Biol. Chem. 283, 16790-16800.
248. Wakshlag, J., Antonyak, M., Boehm, J., Boehm, K., and Cerione, R. (2006) Effects of tissue transglutaminase on β -amyloid1-42-induced apoptosis, Protein J. 25, 83-94.
249. Johnson, G., Cox, T., Lockhart, J., Zinnerman, M., Miller, M., and Powers, R. (1997) Transglutaminase activity is increased in Alzheimer's disease brain, Brain Res. 751, 323-329.
250. Nemes, Z., F́es̈us, L., Egerh́azi, A., Keszthelyi, A., and Degrell, I. (2001) N(ε)(γ-glutamyl)lysine in cerebrospinal fluid marks Alzheimer type and vascular dementia, Neurobiol. Aging 22, 403-406.
251. Norlund, M., Lee, J., Zainelli, G., and Muma, N. (1999) Elevated transglutaminaseinduced bonds in PHF tau in Alzheimer's disease, Brain Res. 851, 154-163.
252. Singer, S., Zainelli, G., Norlund, M., Lee, J., and Muma, N. (2002) Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease, Neurochem. Int. 40, 17-30.
253. Nemes, Z., Devreese, B., Steinert, P., Van Beeumen, J., and F́es̈us, L. (2004) Crosslinking of ubiquitin, HSP27, parkin, and γ-synuclein by γ-glutamyl-ε-lysine bonds in Alzheimer's neurofibrillary tangles, FASEB J. 18, 1135-1137.
254. Wilhelmus, M., Verhaar, R., Bol, J., van Dam, A., Hoozemans, J., Rozemuller, A., and Drukarch, B. (2011) Novel role of transglutaminase 1 in corpora amylacea formation? Neurobiol. Aging. 32, 845-856.
255. Zemaitaitis, M., Kim, S., Halverson, R., Troncoso, J., Lee, J., and Muma, N. (2003) Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy, J. Neuropathol. Exp. Neurol. 62, 173-184.
256. Zemaitaitis, M., Lee, J., Troncoso, J., and Muma, N. (2000) Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy, J. Neuropathol. Exp. Neurol. 59, 983-989.
257. Tremblay, M., Saint-Pierre, M., Bourhis, E., Ĺevesque, D., Rouillard, C., and Cicchetti, F. (2006) Neuroprotective effects of cystamine in aged parkinsonian mice, Neurobiol. Aging 27, 862-870.
258. Citron, B., Suo, Z., SantaCruz, K., Davies, P., Qin, F., and Festoff, B. (2002) Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration, Neurochem. Int. 40, 69-78.
259. Andringa, G., Lam, K., Chegary, M., Wang, X., Chase, T., and Bennett, M. (2004) Tissue transglutaminase catalyzes the formation of α-synuclein crosslinks in Parkinson's disease, FASEB J. 18, 932-934.
260. Segers-Nolten, I.,Wilhelmus,M., Veldhuis, G., van Rooijen, B., Drukarch, B., and Subramaniam, V. (2008) Tissue transglutaminase modulates α-synuclein oligomerization, Protein Sci. 17, 1395-1402.
261. Schmid, A., Chiappe, D., Pignat, V., Grimminger, V., Hang, I., Moniatte, M., and Lashuel, H. (2009) Dissecting the mechanisms of tissue transglutaminase-induced crosslinking of α-synuclein: implications for the pathogenesis of Parkinson disease, J. Biol. Chem. 284, 13128-13142.
262. Pincus, J. and Waelsch, H. (1968) The specificity of transglutaminase. I. Human hemoglobin as a substrate for the enzyme, Arch. Biochem. Biophys. 126, 34-43.
263. Aeschlimann, D. and Paulsson, M. (1994) Transglutaminases: protein cross-linking enzymes in tissues and body fluids, Thromb. Haemost. 71, 402-415.
264. Lorand, L. (1996) Neurodegenerative diseases and transglutaminase, Proc. Natl. Acad. Sci. U.S.A. 93, 14310-14313.
265. Hettasch, J. and Greenberg, C. (1994) Analysis of the catalytic activity of human factor XIIIa by site-directed mutagenesis, J. Biol. Chem. 269, 28309-28313.
266. Spraggon, G., Everse, S., and Doolittle, R. (1997) Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin, Nature 389, 455-462.
267. Csosz, E., Bagossi, P., Nagy, Z., Dosztanyi, Z., Simon, I., and Fesus, L. (2008) Substrate preference of transglutaminase 2 revealed by logistic regression analysis and intrinsic disorder examination, J. Mol. Biol. 383, 390-402.
268. Greenberg, C., Birckbichler, P., and Rice, R. (1991) Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues, FASEB J. 5, 3071-3077.
269. Aeschlimann, D., Paulsson, M., and Mann, K. (1992) Identification ofGln726 in nidogen as the amine acceptor in transglutaminase-catalyzed cross-linking of laminin-nidogen complexes, J. Biol. Chem. 267, 11316-11321.
270. Parameswaran, K., Velasco, P., Wilson, J., and Lorand, L. (1990) Labeling of ε-lysine crosslinking sites in proteinswith peptide substrates of factorXIIIa and transglutaminase, Proc. Natl. Acad. Sci. U.S.A. 87, 8472-8475.
271. Toda, H. and Folk, J. (1969) Determination of protein-bound glutamine, Biochim. Biophys. Acta 175, 427-430.
272. Tamaki, T. and Aoki, N. (1982) Cross-linking of β 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor, J. Biol. Chem. 257, 14767-14772.
273. Berbers, G., Bentlage, H., Brans, A., Bloemendal, H., and de Jong, W. (1983) β-Crystallin: endogenous substrate of lens transglutaminase. Characterization of the acyldonor site in the β Bp chain, Eur. J. Biochem. 135, 315-320.
274. Berbers, G., Feenstra, R., Van Den Bos, R., Hoekman,W., Bloemendal, H., and de Jong, W. (1984) Lens transglutaminase selects specific β-crystallin sequences as substrate, Proc. Natl. Acad. Sci. U.S.A. 81, 7017-7020.
275. Bowness, J., Folk, J., and Timpl, R. (1987) Identification of a substrate site for liver transglutaminase on the aminopropeptide of type III collagen, J. Biol. Chem. 262, 1022-1024.
276. Chen, R. and Doolittle, R. (1971) - cross-linking sites in human and bovine fibrin, Biochemistry 10, 4487-4491.
277. Coussons, P., Price, N., Kelly, S., Smith, B., and Sawyer, L. (1992) Factors that govern the specificity of transglutaminase-catalysed modification of proteins and peptides, Biochem. J. 282(Pt 3), 929-930.
278. Murthy, S.,Wilson, J., Lukas, T., Kuret, J., and Lorand, L. (1998) Cross-linking sites of the human tau protein, probed by reactions with human transglutaminase, J. Neurochem. 71, 2607-2614.
279. Ferŕandiz, C., Ṕerez-Paýa, E., Braco, L., and Abad, C. (1994) Gln5 selectively monodansylated substance P as a sensitive tool for interaction studies with membranes, Biochem. Biophys. Res. Commun. 203, 359-365.
280. Pastor,M., Diez, A., Ṕerez-Paýa, E., and Abad,C. (1999) Addressing substrate glutamine requirements for tissue transglutaminase using substance P analogues, FEBS Lett. 451, 231-234.
281. Gorman, J. and Folk, J. (1980) Structural features of glutamine substrates for human plasma factor XIIIa (activated blood coagulation factor XIII). J. Biol. Chem. 255, 419-427.
282. Gorman, J. and Folk, J. (1981) Structural features of glutamine substrates for transglutaminases. Specificities of human plasma factor XIIIa and the guinea pig liver enzyme toward synthetic peptides, J. Biol. Chem. 256, 2712-2715.
283. Gorman, J. and Folk, J. (1984) Structural features of glutamine substrates for transglutaminases. Role of extended interactions in the specificity of human plasma factor XIIIa and of the guinea pig liver enzyme, J. Biol. Chem. 259, 9007-9010.
284. Gross, M., Whetzel, N., and Folk, J. (1975) The extended active site of guinea pig liver transglutaminase, J. Biol. Chem. 250, 4648-4655.
285. Sollid, L. (2002) Coeliac disease: dissecting a complex inflammatory disorder, Nat. Rev. Immunol. 2, 647-655.
286. Dieterich, W., Ehnis, T., Bauer, M., Donner, P., Volta, U., Riecken, E., and Schuppan, D. (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease, Nat. Med. 3, 797-801.
287. Molberg, O., Mcadam, S., K̈orner, R., Quarsten, H., Kristiansen, C.,Madsen, L., Fugger, L., Scott, H., Noŕen, O., Roepstorff, P., Lundin, K., Sj̈ostr̈om, H., and Sollid, L. (1998) Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease, Nat. Med. 4, 713-717.
288. Shan, L., Molberg, Ø., Parrot, I., Hausch, F., Filiz, F., Gray, G., Sollid, L., and Khosla, C. (2002) Structural basis for gluten intolerance in celiac sprue, Science 297, 2275-2279.
289. Mowat, A. (2003) Coeliac disease-a meeting point for genetics, immunology, and protein chemistry, Lancet 361, 1290-1292.
290. Fleckenstein, B., Molberg, Ø., Qiao, S., Schmid, D., von der M̈ulbe, F., Elgstøen, K., Jung, G., and Sollid, L. (2002) Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process, J. Biol. Chem. 277, 34109-34116.
291. Parameswaran, K., Cheng, X., Chen, E., Velasco, P., Wilson, J., and Lorand, L. (1997) Hydrolysis of β:ε isopeptides by cytosolic transglutaminases and by coagulation factor XIIIa, J. Biol. Chem. 272, 10311-10317.
292. oaten, I., Fleckenstein, B., Molberg, O., Khosla, C., and Sollid, L. (2005) Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease, J. Immunol. 174, 1657-1663.
293. Stamnaes, J., Fleckenstein, B., and Sollid, L. (2008) The propensity for deamidation and transamidation of peptides by transglutaminase 2 is dependent on substrate affinity and reaction conditions, Biochim. Biophys. Acta 1784, 1804-1811.
294. Dekking, E., Van Veelen, P., De Ru, A., Kooy-Winkelaar, E., Groneveld, T., Nieuwenhuizen, W., andKonig, F. (2008) Microbial transglutaminase generates T cell stimulatory epitopes involved in celiac disease, J. Cereal Sci. 47, 339-346.
295. Bruce, S., Bjarnason, I., and Peters, T. (1985) Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease, Clin. Sci. (Lond.) 68, 573-579.
296. Piper, J., Gray, G., and Khosla, C. (2002) High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac sprue, Biochemistry 41, 386-393.
297. Skovbjerg, H., Noŕen, O., Anthonsen, D., Moller, J., and Sj̈ostr̈om, H. (2002) Gliadin is a good substrate of several transglutaminases: possible implication in the pathogenesis of coeliac disease, Scand. J. Gastroenterol. 37, 812-817.
298. Arentz-Hansen, H., McAdam, S., Molberg, Ø., Fleckenstein, B., Lundin, K., Jørgensen, T., Jung, G., Roepstorff, P., and Sollid, L. (2002) Celiac lesion T cells recognize epitopesthat cluster in regions of gliadins rich in proline residues, Gastroenterology 123, 803-809.
299. Vader, W., Kooy, Y., Van Veelen, P., De Ru, A., Harris, D., Benckhuijsen, W., Pe{ogonek}na, S., Mearin, L., Drijfhout, J., and Koning, F. (2002) The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides, Gastroenterology 122, 1729-1737.
300. Sugimura, Y., Hosono, M., Wada, F., Yoshimura, T., Maki, M., and Hitomi, K. (2006) Screening for the preferred substrate sequence of transglutaminase using a phagedisplayed peptide library: identification of peptide substrates for TGASE 2 and Factor XIIIA, J. Biol. Chem. 281, 17699-17706.
301. Keresztessy, Z., Csosz, E., H́arsfalvi, J., Csoḿos, K., Gray, J., Lightowlers, R., Lakey, J., Balajthy, Z., and F́es̈us, L. (2006) Phage display selection of efficient glutamine-donor substrate peptides for transglutaminase 2, Protein Sci. 15, 2466-2480.
302. Sugimura, Y., Hosono, M., Kitamura, M., Tsuda, T., Yamanishi, K., Maki, M., and Hitomi, K. (2008) Identification of preferred substrate sequences for transglutaminase 1-development of a novel peptide that can efficiently detect cross-linking enzyme activity in the skin, FEBS J. 275, 5667-5677.
303. Sugimura, Y., Yokoyama, K., Nio, N., Maki, M., and Hitomi, K. (2008) Identification of preferred substrate sequences of microbial transglutaminase from Streptomyces mobaraensis using a phage-displayed peptide library, Arch. Biochem. Biophys. 477, 379-383.
304. Green, H. and Wang, N. (1994) Codon reiteration and the evolution of proteins, Proc. Natl. Acad. Sci. U.S.A. 91, 4298-4302.
305. Hu,B. and Messersmith, P. (2003) Rational design of transglutaminase substrate peptides for rapid enzymatic formation of hydrogels, J. Am. Chem. Soc. 125, 14298-14299.
306. Clarke, D., Mycek,M., Neidle, A., andWaelsch, H. (1959) The Incorporation of Amines into Protein, Arch. Biochem. Biophys. 79, 338-354.
307. Pincus, J. and Waelsch, H. (1968) The specificity of transglutaminase. II. Structural requirements of the amine substrate, Arch. Biochem. Biophys. 126, 44-52.
308. Gross, M., Whetzel, N., and Folk, J. (1977) Amine binding sites in acyl intermediates of transglutaminases. Human blood plasma enzyme (activated coagulation factor XIII) and guinea pig liver enzyme, J. Biol. Chem. 252, 3752-3759.
309. Groenen, P., Bloemendal, H., and de Jong, W. (1992) The carboxy-terminal lysine of β B-crystallin is an amine-donor substrate for tissue transglutaminase, Eur. J. Biochem. 205, 671-674.
310. Groenen, P., Seccia, M., Smulders, R., Gravela, E., Cheeseman, K., Bloemendal, H., and de Jong, W. (1993) Exposure of β H-crystallin to hydroxyl radicals enhances the transglutaminase-susceptibility of its existing amine-donor and amine-acceptor sites, Biochem. J. 295(Pt 2), 399-404.
311. Lorand, L., Velasco, P., Murthy, S., Wilson, J., and Parameswaran, K. (1992) Isolation of transglutaminase-reactive sequences from complex biological systems: a prominent lysine donor sequence in bovine lens, Proc. Natl. Acad. Sci. U.S.A. 89, 11161- 11163.
312. Pucci, P., Malorni, A., Marino, G., Metafora, S., Esposito, C., and Porta, R. (1988) B-endorphin modification by transglutaminase in vitro: identification by FAB/MS of glutamine-11 and lysine-29 as acyl donor and acceptor sites, Biochem. Biophys. Res. Commun. 154, 735-740.
313. Clement, S., Velasco, P., Murthy, S.,Wilson, J., Lukas, T., Goldman, R., and Lorand, L. (1998) The intermediate filament protein, vimentin, in the lens is a target for cross-linking by transglutaminase, J. Biol. Chem. 273, 7604-7609.
314. Murthy, S., Lukas, T., Jardetzky, T., and Lorand, L. (2009) Selectivity in the posttranslational, transglutaminase-dependent acylation of lysine residues, Biochemistry 48, 2654-2660.
315. Groenen, P., Grootjans, J., Lubsen, N., Bloemendal, H., and de Jong, W. (1994) Lys-17 is the amine-donor substrate site for transglutaminase in β A3-crystallin, J. Biol. Chem. 269, 831-833.
316. Grootjans, J., Groenen, P., and de Jong, W. (1995) Substrate requirements for transglutaminases. Influence of the amino acid residue preceding the amine donor lysine in a native protein, J. Biol. Chem. 270, 22855-22858.
317. Groenen, P., Smulders, R., Peters, R., Grootjans, J., Van Den Ijssel, P., Bloemendal, H., and de Jong, W. (1994) The amine-donor substrate specificity of tissue-type transglutaminase. Influence of amino acid residues flanking the amine-donor lysine residue, Eur. J. Biochem. 220, 795-799.
318. McDonagh, J. and Fukue, H. (1996) Determinants of substrate specificity for factor XIII, Semin. Thromb. Hemost. 22, 369-376.
319. Chung, S. (1972) Comparative studies on tissue transglutaminase and factor XIII, Ann. N. Y. Acad. Sci. 202, 240-255.
320. Hettasch, J., Peoples, K., and Greenberg, C. (1997) Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras, J. Biol. Chem. 272, 25149-25156.
321. Shainoff, J., Urbanic, D., and DiBello, P. (1991) Immunoelectrophoretic characterizations of the cross-linking of fibrinogen and fibrin by factor XIIIa and tissue transglutaminase. Identification of a rapid mode of hybrid α-/γ-chain cross-linking that is promoted by the β-chain cross-linking, J. Biol. Chem. 266, 6429-6437.
322. Tarcsa, E., Marekov, L., Andreoli, J., Idler, W., Candi, E., Chung, S., and Steinert, P. (1997) The fate of trichohyalin. Sequential post-translational modifications by peptidylarginine deiminase and transglutaminases, J. Biol. Chem. 272, 27893-27901.
323. Robinson, N., Baker, P., Jones, C., and Aplin, J. (2007)Arole for tissue transglutaminase in stabilization of membrane-cytoskeletal particles shed from the human placenta, Biol. Reprod. 77, 648-657.
324. Ichikawa, A., Ishizaki, J., Morita, M., Tanaka, K., and Ikura, K. (2008) Identification of new amine acceptor protein substrate candidates of transglutaminase in rat liver extract: use of 5-(biotinamido) pentylamine as a probe, Biosci. Biotechnol. Biochem. 72, 1056-1062.
325. Orru, S., Caputo, I., D'Amato, A., Ruoppolo, M., and Esposito, C. (2003) Proteomics identification of acyl-acceptor and acyl-donor substrates for transglutaminase in a humanintestinal epithelial cell line. Implications for celiac disease, J. Biol. Chem. 278, 31766-31773.
326. Wilhelmus, M., van Dam, A., and Drukarch, B. (2008) Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases, Eur. J. Pharmacol. 585, 464-472.
327. Hoffner, G., Andŕe, W., Vanhoutteghem, A., Sou'es, S., and Djian, P. (2010) Transglutaminase-catalyzed cross linking in neurological disease: from experimental evidence to therapeutic inhibition, CNS Neurol. Disord. Drug Targets 9, 217-231.
328. Gentile, V. and Cooper, A. (2004) Transglutaminases - possible drug targets in human diseases, Curr. Drug Targets CNS Neurol. Disord. 3, 99-104.
329. Sollid, L. and Khosla, C. (2005) Future therapeutic options for celiac disease, Nat. Clin. Pract. Gastroenterol. Hepatol. 2, 140-147.
330. Siegel, M., Bethune, M., Gass, J., Ehren, J., Xia, J., Johannsen, A., Stuge, T., Gray, G., Lee, P., and Khosla, C. (2006) Rational design of combination enzyme therapy for celiac sprue, Chem. Biol. 13, 649-658.
331. Kim, S. Y. (2006) Transglutaminase 2 in inflammation, Front. Biosci. 11, 3026- 3035.
332. Pinkas, D. M., Strop, P., Brunger, A. T., and Khosla, C. (2007) Transglutaminase 2 undergoes a large conformational change upon activation, PLoS Biol. 5, e327.
333. Falasca, L., Farrace, M. G., Rinaldi, A., Tuosto, L., Melino, G., and Piacentini, M. (2008) Transglutaminase type II is involved in the pathogenesis of endotoxic shock, J. Immunol. 180, 2616-2624.
334. Maiuri, L., Luciani, A., Giardino, I., Raia, V., Villella, V., D'Apolito, M., Pettoello-Mantovani, M., Guido, S., Ciacci, C., Cimmino, M., Cexus, O., Londei, M., and Quaratino, S. (2008) Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARγ down-regulation, J. Immunol. 180, 7697-7705.
335. Elli, L., Bergamini, C., Bardella, M., and Schuppan, D. (2009) Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver, Dig. Liver Dis. 41, 541-550.
336. Siegel, M. and Khosla, C. (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states, Pharmacol. Ther. 115, 232-245.
337. Verma, A. and Mehta, K. (2007) Tissue transglutaminase-mediated chemoresistance in cancer cells, Drug Resist Updat 10, 144-151.
338. Kotsakis, P. and Griffin,M. (2007) Tissue transglutaminase in tumour progression: friend or foe? Amino Acids 33, 373-384.
339. Ai, L., Kim,W. J., Demircan, B., Dyer, L.M., Bray, K. J., Skehan, R. R., Massoll, N. A., and Brown, K. D. (2008) The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer, Carcinogenesis 29, 510-518.
340. Jiang, W., Ablin, R., Kynaston, H., and Mason, M. (2009) The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway, Microvasc. Res. 77, 150- 157.
341. Uemura, N., Nakanishi, Y., Kato, H., Saito, S., Nagino, M., Hirohashi, S., and Kondo, T. (2009) Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics, Int. J. Cancer 124, 2106-2115.
342. Park, K., Kim, H., Lee, J., Choi, Y., Park, S., Yang, S., Kim, S., and Hong, K. (2010) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer, J. Cancer Res. Clin. Oncol. 136, 493-502.
343. Kim, D., Park, K., Jeong, K., Lee, B., Lee, C., and Kim, S. (2009) Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition, Cancer Lett. 273, 243-249.
344. Molberg, Ø., Solheim Flaete, N., Jensen, T., Lundin, K., Arentz-Hansen, H., Anderson, O., Kjersti Uhlen, A., and Sollid, L. (2003) Intestinal T-cell responses to high-molecularweight glutenins in celiac disease, Gastroenterology 125, 337-344.
345. Maiuri, L., Ciacci, C., Ricciardelli, I.,Vacca, L., Raia,V., Rispo, A., Griffin,M., Issekutz, T., Quaratino, S., and Londei, M. (2005) Unexpected role of surface transglutaminase type II in celiac disease, Gastroenterology 129, 1400-1413.
346. Case, A. and Stein, R. (2007) Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor, Biochemistry 46, 1106-1115.
347. Pardin, C., Pelletier, J., Lubell,W., and Keillor, J. (2008) Cinnamoyl inhibitors of tissue transglutaminase, J. Org. Chem. 73, 5766-5775.
348. Hausch, F., Halttunen, T.,M̈aki, M., and Khosla, C. (2003) Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase, Chem. Biol. 10, 225-231.
349. Griffin, M., Mongeot, A., Collighan, R., Saint, R., Jones, R., Coutts, I., and Rathbone, D. (2008) Synthesis of potent water-soluble tissue transglutaminase inhibitors, Bioorg. Med. Chem. Lett. 18, 5559-5562.
350. Jager, M., Nir, E., and Weiss, S. (2006) Site-specific labeling of proteins for singlemolecule FRET by combining chemical and enzymatic modification, Protein Sci. 15, 640-646.
351. Valdivia, A., Villalonga, R., Di Pierro, P., Ṕerez, Y., Mariniello, L., Ǵomez, L., and Porta, R. (2006) Transglutaminase-catalyzed site-specific glycosidation of catalase with aminated dextran, J. Biotechnol. 122, 326-333.
352. Sugimura, Y., Ueda, H., Maki, M., and Hitomi, K. (2007) Novel site-specific immobilization of a functional protein using a preferred substrate sequence for transglutaminase 2, J. Biotechnol. 131, 121-127.
353. Csosz, E., Mesḱo, B., and F́es̈us, L. (2009) Transdab wiki: the interactive transglutaminase substrate database on web 2.0 surface, Amino Acids 36, 615-617.
354. Facchiano, A., Facchiano, A., and Facchiano, F. (2003) Active Sequences Collection (ASC) database: a new tool to assign functions to protein sequences, Nucleic Acids Res. 31, 379-382.